Définition et standardisation des bilans d’histocompatibilité en fonction du parcours du patient et du type de donneur : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC) et de la Société Francophone d’Histocompatibilité et Immunogénétique (SFHI)
| Autor: | Mamy Ralazamahaleo, Paul-Olivier Rouzaire, Ibrahim Yakoub-Agha, M Fort, Kahina Amokrane, Valérie Dubois, Nicolas Guillaume, Sandra Michiels, Anne Kennel, Catherine Faucher, Roberto Crocchiolo |
|---|---|
| Přispěvatelé: | Role of intra-Clonal Heterogeneity and Leukemic environment in ThErapy Resistance of chronic leukemias (CHELTER), Université Clermont Auvergne (UCA) |
| Jazyk: | francouzština |
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Cancer Research Standardization High resolution 03 medical and health sciences 0302 clinical medicine Time frame Medicine Radiology Nuclear Medicine and imaging Hla antibodies ComputingMilieux_MISCELLANEOUS Hematopoietic cell business.industry [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology Hematology General Medicine Matched Unrelated Donor medicine.disease 3. Good health Histocompatibility 030104 developmental biology Oncology 030220 oncology & carcinogenesis Medical emergency Quality level business |
| Zdroj: | Bulletin du Cancer Bulletin du Cancer, John Libbey Eurotext, 2021, ⟨10.1016/j.bulcan.2021.01.024⟩ |
| ISSN: | 0007-4551 1769-6917 |
| Popis: | Standardization of histocompatibility tests for allogeneic hematopoietic cell transplants, harmonization of information transmitted to clinicians are part of quality improvement and optimization of human and economic resources. New HLA typing technologies provide high-resolution information within a reasonable time frame. Knowledge of high-resolution HLA typing for the patient and their relatives is essential for a better interpretation of compatibilities. HLA-DPB1 typing must be considered in transplant field regardless of the donor type. The benefits of using search and match programs are considerable. It saves time and reduces additional typing costs by providing rapid information about the likelihood to identify a matched unrelated donor. A backup therapy considering alternative cell sources or treatment can therefore be quickly implemented. The importance of knowledge and consideration of patient immunization for donor choice was explored in previous workshops of the SFGM-TC (2018 and 2019). The published recommendations remain applicable. The routine follow-up protocol and in case of desensitization will be detailed here. This harmonization must be accompanied by the standardization of information to be returned to the clinician regarding the donor finding possibilities for the patient. This will guarantee a similar quality level in every center. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|